Data published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 AIM ImmunoTech Inc. today announced the publication of results from the Phase 1 study at Roswell Park.
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response + microinvasive residual disease at 66%, comparable to.
Investegate | Company Announcement investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.